611 related articles for article (PubMed ID: 28034281)
21. Treatment characteristics, efficacy and safety of thrombopoietin analogues in routine management of primary immune thrombocytopenia.
Mingot-Castellano ME; Caparrós IS; Fernández F; Perera-Alvarez MDM; Jimenez-Bárcenas R; Casaus García A; González-Silva M; Yera-Cobo M; Nieto-Hernandez MM; Rodríguez-Fernandez MJ; Díaz-Canales D
Blood Coagul Fibrinolysis; 2018 Jun; 29(4):374-380. PubMed ID: 29738335
[TBL] [Abstract][Full Text] [Related]
22. Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice.
Ptushkin VV; Vinogradova OY; Pankrashkina MM; Chernikov MV; Arshanskaya EG; Tkachenko NE
Ter Arkh; 2018 Aug; 90(7):70-76. PubMed ID: 30701925
[TBL] [Abstract][Full Text] [Related]
23. Thrombopoietin: too much or too little.
Newland A
Hematology; 2012 Apr; 17 Suppl 1():S166-8. PubMed ID: 22507811
[TBL] [Abstract][Full Text] [Related]
24. New therapeutic options for immune thrombocytopenia.
Schipperus M; Fijnheer R
Neth J Med; 2011; 69(11):480-5. PubMed ID: 22173361
[TBL] [Abstract][Full Text] [Related]
25. Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study.
Neunert C; Despotovic J; Haley K; Lambert MP; Nottage K; Shimano K; Bennett C; Klaassen R; Stine K; Thompson A; Pastore Y; Brown T; Forbes PW; Grace RF;
Pediatr Blood Cancer; 2016 Aug; 63(8):1407-13. PubMed ID: 27135461
[TBL] [Abstract][Full Text] [Related]
26. [Thrombosis during thrombopoietin receptor agonist treatment for immune thrombocytopenia. A French multicentric observational study].
Weber E; Moulis G; Mahévas M; Guy C; Lioger B; Durieu I; Hunault M; Ramanantsoa M; Royer B; Default A; Pérault-Pochat MC; Moachon L; Bernard N; Bardy G; Jonville-Bera AP; Geniaux H; Godeau B; Cathébras P
Rev Med Interne; 2017 Mar; 38(3):167-175. PubMed ID: 27793553
[TBL] [Abstract][Full Text] [Related]
27. Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura.
Stasi R; Evangelista ML; Amadori S
Drugs; 2008; 68(7):901-12. PubMed ID: 18457458
[TBL] [Abstract][Full Text] [Related]
28. Romiplostim in chronic immune thrombocytopenic purpura.
Cersosimo RJ
Clin Ther; 2009 Sep; 31(9):1887-907. PubMed ID: 19843480
[TBL] [Abstract][Full Text] [Related]
29. What is publication? The case of eltrombopag.
Benham L; Guo L; Turner R
Lancet; 2011 Jan; 377(9763):360-1. PubMed ID: 21277427
[No Abstract] [Full Text] [Related]
30. Thrombopoietin-receptor agonists for children with immune thrombocytopenia: a systematic review.
Zhang J; Liang Y; Ai Y; Xie J; Li Y; Zheng W
Expert Opin Pharmacother; 2017 Oct; 18(15):1543-1551. PubMed ID: 28845713
[TBL] [Abstract][Full Text] [Related]
31. Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists.
Ghadaki B; Nazi I; Kelton JG; Arnold DM
Transfusion; 2013 Nov; 53(11):2807-12. PubMed ID: 23451917
[TBL] [Abstract][Full Text] [Related]
32. Thrombopoietin-receptor agonists in haematological disorders: the Danish experience.
Gudbrandsdottir S; Frederiksen H; Hasselbalch H
Platelets; 2012; 23(6):423-9. PubMed ID: 22185370
[TBL] [Abstract][Full Text] [Related]
33. Thrombopoietin receptor agonists: ten years later.
Ghanima W; Cooper N; Rodeghiero F; Godeau B; Bussel JB
Haematologica; 2019 Jun; 104(6):1112-1123. PubMed ID: 31073079
[TBL] [Abstract][Full Text] [Related]
34. Eltrombopag versus romiplostim in treatment of adult patients with immune thrombocytopenia: A systematic review incorporating an indirect-comparison meta-analysis.
Zhang J; Liang Y; Ai Y; Li X; Xie J; Li Y; Zheng W; He R
PLoS One; 2018; 13(6):e0198504. PubMed ID: 29856837
[TBL] [Abstract][Full Text] [Related]
35. Romiplostim for the management of pediatric immune thrombocytopenia: drug development and current practice.
Neunert CE; Rose MJ
Blood Adv; 2019 Jun; 3(12):1907-1915. PubMed ID: 31239245
[TBL] [Abstract][Full Text] [Related]
36. New thrombopoietin receptor agonists for platelet disorders.
Homeida S; Ebdon C; Batty P; Jackson B; Kolade S; Bateman C; Peng YY; Stasi R
Drugs Today (Barc); 2012 Apr; 48(4):293-301. PubMed ID: 22536571
[TBL] [Abstract][Full Text] [Related]
37. Sustained remission of chronic immune thrombocytopenia after discontinuation of treatment with thrombopoietin-receptor agonists in adults.
Červinek L; Mayer J; Doubek M
Int J Hematol; 2015 Jul; 102(1):7-11. PubMed ID: 25833724
[TBL] [Abstract][Full Text] [Related]
38. The Cost-effectiveness of Eltrombopag for the Treatment of Immune Thrombocytopenia in the United States.
Tremblay G; Dolph M; Roy AN; Said Q; Forsythe A
Clin Ther; 2020 May; 42(5):860-872.e8. PubMed ID: 32199608
[TBL] [Abstract][Full Text] [Related]
39. Use of thrombopoietin receptor agonists in adults with immune thrombocytopenia: a systematic review and Central European expert consensus.
Pulanić D; Bátorová A; Bodó I; Červinek L; Ionita I; Lissitchkov T; Melikyan A; Podolak-Dawidziak M
Ann Hematol; 2023 Apr; 102(4):715-727. PubMed ID: 36826482
[TBL] [Abstract][Full Text] [Related]
40. Glucocorticoids promote response to thrombopoietin-receptor agonists in refractory ITP: a case series.
Poston JN; Gernsheimer TB
Int J Hematol; 2019 Aug; 110(2):255-259. PubMed ID: 30972617
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
